Abstract

IntroductionMatrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tissue inhibitors of metalloproteinase-1 (TIMP-1) in individuals with AD dementia and cognitively healthy elderly individuals, and to investigate their relationship with established CSF biomarkers for Alzheimer's disease.MethodsCSF was collected from 38 individuals with AD dementia and 34 cognitively healthy elderly individuals. The CSF was analyzed for MMP-1, MMP-3, MMP-9, TIMP-1, β-amyloid1-42 (Aβ42), total tau protein (T-tau) and phosphorylated tau protein (P-tau). MMP/TIMP-1 ratios were calculated. APOE genotype was determined for the participants.ResultsAD patients had higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy individuals. In AD patients, the MMP-9/TIMP-1 ratio correlated with CSF T-tau, a marker of neurodegeneration. Interestingly, the cognitively healthy individuals with risk markers for future AD, i.e. AD-supportive CSF biomarker levels of T-tau, P-tau and Aβ42 or the presence of the APOE ε4 allele, had higher CSF MMP-3 and MMP-9 levels and higher CSF MMP-3/TIMP-1 ratios compared to the healthy individuals without risk markers. The CSF levels of MMP-3 and -9 in the control group also correlated with the CSF T-tau and P-tau levels.ConclusionsThis study indicates that MMP-3 and MMP-9 might be involved in early pathogenesis of AD and that MMPs could be associated with neuronal degeneration and formation of neurofibrillary tangles even prior to development of overt cognitive dysfunction.

Highlights

  • Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer’s disease (AD)

  • Increased cerebrospinal fluid (CSF) total tau protein (T-tau) levels correlated with high CSF MMP-9/tissue inhibitor of metalloproteinase (TIMP)-1 ratios and MMP3/tissue inhibitors of metalloproteinase-1 (TIMP-1) ratios in the AD patients (Figures 1 and 2)

  • In the present study we show that AD patients have a higher MMP-9/TIMP-1 ratio and a lower TIMP-1 level in CSF compared with cognitively healthy elderly individuals and that the MMP-9/TIMP-1 ratio in AD patients correlates with CSF T-tau, a marker of neuronal degeneration

Read more

Summary

Introduction

Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer’s disease (AD). Most cases of dementia are caused by Alzheimer’s disease (AD), which is characterized by progressive accumulation of senile plaques, containing b-amyloid (Ab), and neurofibrillary tangles, containing hyperphosphorylated tau [1]. This process probably starts many years before the typical clinical symptoms of AD appear. There is increasing evidence indicating that matrix metalloproteinases (MMPs) may play an important but complex role in the pathology behind neurodegenerative disorders [2,3,4]. MMPs are zinc- and which it is being expressed. Their beneficial effects include neurogenesis, angiogenesis, myelinogenesis, axonal growth, and apoptosis inhibition, whereas examples of detrimental effects are apoptosis induction, blood brain barrier disruption and demyelination [2,3,5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call